Drug Profile
Research programme: dry eye syndrome therapy - arGentis LLC
Alternative Names: ARG 101(T); ARG 102(P); ARG 103; T4DE; T4DE - arGentisLatest Information Update: 13 Nov 2021
Price :
$50
*
At a glance
- Originator Argentis LLC
- Developer arGentis Pharmaceuticals
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Progesterone receptor agonists; Testosterone agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dry eyes
Most Recent Events
- 26 Nov 2015 Discontinued - Preclinical for Dry eyes in USA (Topical)
- 24 May 2009 No development reported - Preclinical for Dry eyes in USA (Topical)
- 16 Jan 2007 arGentis licenses transdermal progesterone in the treatment of Dry Eye Syndrome from Southern College of Optometry